203 related articles for article (PubMed ID: 25606676)
21. Profound ligand-independent kinase activation of fibroblast growth factor receptor 3 by the activation loop mutation responsible for a lethal skeletal dysplasia, thanatophoric dysplasia type II.
Webster MK; D'Avis PY; Robertson SC; Donoghue DJ
Mol Cell Biol; 1996 Aug; 16(8):4081-7. PubMed ID: 8754806
[TBL] [Abstract][Full Text] [Related]
22. Thanatophoric dysplasia type I with syndactyly.
Brodie SG; Kitoh H; Lipson M; Sifry-Platt M; Wilcox WR
Am J Med Genet; 1998 Nov; 80(3):260-2. PubMed ID: 9843049
[TBL] [Abstract][Full Text] [Related]
23. FGFR3 unliganded dimer stabilization by the juxtamembrane domain.
Sarabipour S; Hristova K
J Mol Biol; 2015 Apr; 427(8):1705-14. PubMed ID: 25688803
[TBL] [Abstract][Full Text] [Related]
24. Clinical features and molecular genetic analysis of thanatophoric dysplasia type I in a neonate with a de novo c.2419 T > C (p. Ter807Arg) (X807R) mutation in FGFR3.
Jiang G; Chen X; Dai D; Cao L; Qian L
Exp Mol Pathol; 2019 Dec; 111():104297. PubMed ID: 31476288
[TBL] [Abstract][Full Text] [Related]
25. A novel FGFR3-binding peptide inhibits FGFR3 signaling and reverses the lethal phenotype of mice mimicking human thanatophoric dysplasia.
Jin M; Yu Y; Qi H; Xie Y; Su N; Wang X; Tan Q; Luo F; Zhu Y; Wang Q; Du X; Xian CJ; Liu P; Huang H; Shen Y; Deng CX; Chen D; Chen L
Hum Mol Genet; 2012 Dec; 21(26):5443-55. PubMed ID: 23014564
[TBL] [Abstract][Full Text] [Related]
26. Incidence of fibroblast growth factor receptor 3 gene (FGFR3) A248C, S249C, G372C, and T375C mutations in bladder cancer.
Dodurga Y; Tataroglu C; Kesen Z; Satiroglu-Tufan NL
Genet Mol Res; 2011 Jan; 10(1):86-95. PubMed ID: 21264819
[TBL] [Abstract][Full Text] [Related]
27. FGFR3 dimer stabilization due to a single amino acid pathogenic mutation.
Li E; You M; Hristova K
J Mol Biol; 2006 Feb; 356(3):600-12. PubMed ID: 16384584
[TBL] [Abstract][Full Text] [Related]
28. Rapid detection of common mutations of the FGFR3 gene causing thanatophoric dysplasia type I: two case reports.
Yang Y; Liu YN; Li DZ
Fetal Pediatr Pathol; 2012 Jun; 31(3):128-33. PubMed ID: 22414243
[TBL] [Abstract][Full Text] [Related]
29. Long-term survival in typical thanatophoric dysplasia type 1.
Baker KM; Olson DS; Harding CO; Pauli RM
Am J Med Genet; 1997 Jun; 70(4):427-36. PubMed ID: 9182787
[TBL] [Abstract][Full Text] [Related]
30. An unusual radiological finding in thanatophoric dysplasia type 1 with common mutation of the fibroblast growth factor receptor-3 (FGFR3) gene (Arg248Cys).
Camera G; Baldi M; Baffico M; Pozzolo S
Am J Med Genet; 1997 Jul; 71(1):122-3. PubMed ID: 9215781
[No Abstract] [Full Text] [Related]
31. Improved diagnosis of a common mutation (R248C) in the human growth factor receptor 3 (FGFR3) gene that causes type I Thanatophoric dysplasia.
Simsek M; Al-Gazali L; Al-Mjeni R; Bayoumi R
Clin Biochem; 2003 Mar; 36(2):151-3. PubMed ID: 12633765
[No Abstract] [Full Text] [Related]
32. A case of thanatophoric dysplasia type 2: a novel mutation.
Gülaşı S; Atıcı A; Çelik Y
J Clin Res Pediatr Endocrinol; 2015 Mar; 7(1):73-6. PubMed ID: 25800480
[TBL] [Abstract][Full Text] [Related]
33. Physical basis behind achondroplasia, the most common form of human dwarfism.
He L; Horton W; Hristova K
J Biol Chem; 2010 Sep; 285(39):30103-14. PubMed ID: 20624921
[TBL] [Abstract][Full Text] [Related]
34. Molecular, radiologic, and histopathologic correlations in thanatophoric dysplasia.
Wilcox WR; Tavormina PL; Krakow D; Kitoh H; Lachman RS; Wasmuth JJ; Thompson LM; Rimoin DL
Am J Med Genet; 1998 Jul; 78(3):274-81. PubMed ID: 9677066
[TBL] [Abstract][Full Text] [Related]
35. Sprouty 2 disturbs FGFR3 degradation in thanatophoric dysplasia type II: a severe form of human achondroplasia.
Guo C; Degnin CR; Laederich MB; Lunstrum GP; Holden P; Bihlmaier J; Krakow D; Cho YJ; Horton WA
Cell Signal; 2008 Aug; 20(8):1471-7. PubMed ID: 18485666
[TBL] [Abstract][Full Text] [Related]
36. Missense FGFR3 mutations create cysteine residues in thanatophoric dwarfism type I (TD1).
Rousseau F; el Ghouzzi V; Delezoide AL; Legeai-Mallet L; Le Merrer M; Munnich A; Bonaventure J
Hum Mol Genet; 1996 Apr; 5(4):509-12. PubMed ID: 8845844
[TBL] [Abstract][Full Text] [Related]
37. Reduced binding of FGF1 to mutant fibroblast growth factor receptor 3.
Khnykin D; Olsnes S
Growth Factors; 2006 Jun; 24(2):111-9. PubMed ID: 16801131
[TBL] [Abstract][Full Text] [Related]
38. Brain malformation with loss of normal FGFR3 expression in thanatophoric dysplasia type I.
Itoh K; Pooh R; Kanemura Y; Yamasaki M; Fushiki S
Neuropathology; 2013 Dec; 33(6):663-6. PubMed ID: 23551494
[TBL] [Abstract][Full Text] [Related]
39. G370C mutation in the FGFR3 gene in a Japanese patient with thanatophoric dysplasia.
Katsumata N; Kuno T; Miyazaki S; Mikami S; Nagashima-Miyokawa A; Nimura A; Horikawa R; Tanaka T
Endocr J; 1998 Apr; 45 Suppl():S171-4. PubMed ID: 9790257
[TBL] [Abstract][Full Text] [Related]
40. A THANATOPHORIC DYSPLASIA TYPE I CASE WITH A FGFR3 P.R248C MUTATION AND SURVIVAL BEYOND THE NEONATAL PERIOD.
Sahin S; Ograg H; Aslan EA; Akcan AB; Turkmen MK; Moosa S; Elcioglu NH
Genet Couns; 2016; 27(4):513-517. PubMed ID: 30226972
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
